Substituted indolizines and derivatives as CNS agents

Details Substituted indolizines and derivatives as CNS agents Substituted indolizines and derivatives as CNS agents

2005-10-27

2009-10-27

Andres, Janet L (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S112000

Reexamination Certificate

active

07608626

ABSTRACT:
Compounds of formula 1 or pharmaceutically acceptable salts thereof are provided:which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

REFERENCES:
patent: 2002/0002749 (2002-01-01), Breton et al.
patent: 2003/0134843 (2003-07-01), Lubisch et al.
patent: 19907701 (2000-08-01), None
patent: 0 213 696 (1987-03-01), None
patent: 0 252 643 (1988-01-01), None
patent: 0 279 125 (1988-08-01), None
patent: 0 167 901 (1990-04-01), None
patent: 0 213 696 (1991-01-01), None
patent: 0 279 125 (1992-04-01), None
patent: 1129691 (2001-05-01), None
patent: 0 950 661 (2003-11-01), None
patent: 92/21678 (1992-12-01), None
patent: 95/04737 (1995-02-01), None
patent: 95/07279 (1995-03-01), None
patent: 97/11074 (1997-03-01), None
patent: 00/06564 (2000-02-01), None
patent: 00/12510 (2000-03-01), None
patent: 00/34242 (2000-06-01), None
patent: 01/05789 (2001-01-01), None
patent: 01/74814 (2001-10-01), None
patent: 02/051844 (2002-07-01), None
Marazziti et al., Neurochemistry International, vol. 42, 2003, pp. 511-516.
Cingolani et al., European Journal of medicinal chemistry, 1988, vol. 23, pp. 291-294.
Cingolani et al., European Journal of medicinal chemistry, 1990, vol. 25, pp. 709-712.
Ames, D. E. et al., “The preparation of aminoalkylpyrrocolines,”Journal of The Chemical Society, Chemical Society. Letchworth, GB, 1959, pp. 620-622, XP-002083697.
Cingolani, G. M. et al., “Indolizine derivatives with biological activity V. 1-(2-Aminoethyl)-2-methylindolizine and itsN-alkyl derivatives,”Eur. J. Med. Chem., 1988, 23(3), 291-294, XP-002378332.
Walter, L. A. et al., “2-Phenylindolizines,”Journal of Medicinal Chemistry, 1967, 10(3), 498-499.
Allison, D. B. et al., “Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis,”Am. J. Psychiatry, 1999, 156, 1686-1696.
Bundgaard, H. (ed.),Design of Prodrugs, Elsevier (1985), Ch. 1 (pp. 1-92), Ch. 4 (pp. 157-176), Ch. 5 (pp. 177-198), and Ch. 6 (pp. 199-241).
Bundgaard, H. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties,”J. of Pharmaceutical Sciences, Apr. 1988, 77(4), 285-298.
Bundgaard, H., “Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Deliver Reviews, 1992, 8, 1-38.
CAS Registry 101350-38-3, Apr. 5, 1986.
Cingolani, G. M. et al., “Indolizine derivatives with biological activity VI 1-(2-aminoethyl)-3-benzyl-7-methoxy-2-methylindolizine, benanserin structural analogue,”Eur. J. Med. Chem., 1990, 25, 709-712.
Cowen, P. J. et al., “Hypophagic, Endocrine and Subjective Responses tom-Chlorophenylpiperazine in Healthy Men and Women,”Human Psychopharmacology, 1995, 10, 385-391.
Dalton, L.K. et al., “Synthesis of Benz[b]indolizines and related Compounds,”Aust. J. Chem. 1969 22, 1525-1530.
Di Giovanni, G. et al., “Preferential Modulation of Mesolimbic Vs. Nigrostriatal Dopaminergic Function by Serotonin2C/2BReceptor Agonists: A Combined In Vivo Electrophysiological and Microdialysis Study,”Synapse, 2000, 35, 53-61.
Di Matteo, V. et al., “SB 242 084, a selective serotonin2Creceptor antagonist, increases dopaminergic transmissions in the mesolimbic system,”Nueropharmacology, 1999, 38, 1195-1205.
Di Matteo, V. et al., “Selective blockade of serotonin2C/2Breceptors enhances dopamine release in the rat nucleus accumbens,”Nueropharmacology, 1998, 37, 265-272.
Eliel, E. L.,Stereochemistry of Carbon Compounds, McGraw Hill, NY (1962) Ch. 4, pp. 46-87.
Fox, S. H. et al., “Behavioral Effects of 5-HT2CReceptor Antagonism in the Substantia Nigra Zona Reticulata of the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease,”Experimental Neurology, 1998, 151, 35-49.
Higuchi and Stella (eds.),Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975), pp. 1-115 and 196-223.
Jacques, J. et al.,Enantiomers, Racemates and Resolutions, Wiley Interscience, NY (1981) pp. 251-434.
Krogsgaard-Larsen, et al., (ed).Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191, 1991.
Lowry, O. H. et al., “Protein Measurement With The Folin Phenol Reagent,”J. Biol. Chem., 1951, 193, 265-275.
Masand, P. S., “Weight gain associated with psychotropic drugs,”Exp. Opin. Pharmacother., 2000, 1, 377-389.
Millan, M. J. et al., “Serotonin (5-HT)2Creceptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo,”Neuropharmacology, 1998, 37, 953-955.
Remington's Pharmaceutical Sciences, 17thEd., Gennaro, A. R. (Ed.), Mack Publishing Company, Easton, PA (1985) pp. 1409-1677.
Rosenzweig-Lipson, S. et al., “Antiobesity-like effects of the selective 5-HT2C Agonist Way-161503,”ASPETAbstract and Poster, 2000.
Schotte, A. et al., “Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding,”Psychopharmacology, 1996, 124, 57-73.
Uchida, T. et al., “Methods for the Construction of the Indolizine Nucleus”,Synthesis1976, 209-236.
Whitaker, R., “Atypical Antipsychotics: A Modest Advance in Treating Schizophrenia,” Spectrum Life Sciences.Decision Resources, Feb. 11, 2000, 2-1 to 2-12.
Widder, et al. (ed.),Methods in Enzymology, vol. 112, Academic Press (1985), pp. 309-396.
Wilen, S.H.Tables of Resolving Agents and Optical Resolutions, pp. 268-298, E.L. Eliel, Ed., University of Notre Dame Press, Notre Dame, IN 1972.
Wilen, S.H., et al., “Strategies in optical resolutions,”Tetrahedron, 1977, 33, 2725- 2736.

Affiliated with

Also associated with

Rating

Substituted indolizines and derivatives as CNS agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted indolizines and derivatives as CNS agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted indolizines and derivatives as CNS agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4119591